+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Erythropoietin Stimulating Agents Market by Type (Darbepoetin Alfa, Epoetin Alfa, Epoetin Beta), Application (Anemia, Antiretroviral Treatment, Cancer Chemotherapy) - Forecast 2024-2030

  • PDF Icon

    Report

  • 189 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5715864
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Erythropoietin Stimulating Agents Market size was estimated at USD 9.84 billion in 2023, USD 10.32 billion in 2024, and is expected to grow at a CAGR of 5.64% to reach USD 14.45 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Erythropoietin Stimulating Agents Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Erythropoietin Stimulating Agents Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Erythropoietin Stimulating Agents Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Biocon Limited, Celltrion, Inc., Cipla Limited, Dr. Reddys Laboratories Ltd., F. Hoffmann-La Roche Ltd., Intas Pharmaceuticals Limited, Johnson & Johnson, Kyowa Kirin Co., Ltd., LG Life Sciences Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Erythropoietin Stimulating Agents Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Darbepoetin Alfa
    • Epoetin Alfa
    • Epoetin Beta
    • Epoetin-Delta
    • Epoetin-Omega
  • Application
    • Anemia
    • Antiretroviral Treatment
    • Cancer Chemotherapy
    • Kidney Disorders
    • Neural Disease
    • Oncology Diseases
    • Wound Healing
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Erythropoietin Stimulating Agents Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Erythropoietin Stimulating Agents Market?
  3. What are the technology trends and regulatory frameworks in the Erythropoietin Stimulating Agents Market?
  4. What is the market share of the leading vendors in the Erythropoietin Stimulating Agents Market?
  5. Which modes and strategic moves are suitable for entering the Erythropoietin Stimulating Agents Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Erythropoietin Stimulating Agents Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of HIV, cancer, and ESRD globally
5.1.1.2. Increasing development of synthetic forms of ESRD with enhanced recombinant DNA technology
5.1.1.3. Favorable government initiatives to increase healthcare infrastructures
5.1.2. Restraints
5.1.2.1. High cost EPO drugs
5.1.3. Opportunities
5.1.3.1. Introduction of novel drugs and cost-efficient biosimilar formulations
5.1.3.2. Ongoing robust research and development activities to develop innovative molecules
5.1.4. Challenges
5.1.4.1. Stringent regulatory protocols for drug approval
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Erythropoietin Stimulating Agents Market, by Type
6.1. Introduction
6.2. Darbepoetin Alfa
6.3. Epoetin Alfa
6.4. Epoetin Beta
6.5. Epoetin-Delta
6.6. Epoetin-Omega
7. Erythropoietin Stimulating Agents Market, by Application
7.1. Introduction
7.2. Anemia
7.3. Antiretroviral Treatment
7.4. Cancer Chemotherapy
7.5. Kidney Disorders
7.6. Neural Disease
7.7. Oncology Diseases
7.8. Wound Healing
8. Americas Erythropoietin Stimulating Agents Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Erythropoietin Stimulating Agents Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Erythropoietin Stimulating Agents Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Amgen Inc.
12.1.2. Biocon Limited
12.1.3. Celltrion, Inc.
12.1.4. Cipla Limited
12.1.5. Dr. Reddys Laboratories Ltd.
12.1.6. F. Hoffmann-La Roche Ltd.
12.1.7. Intas Pharmaceuticals Limited
12.1.8. Johnson & Johnson
12.1.9. Kyowa Kirin Co., Ltd.
12.1.10. LG Life Sciences Ltd.
12.1.11. Pfizer Inc.
12.1.12. Sun Pharmaceutical Industries Ltd.
12.1.13. Teva Pharmaceutical Industries Ltd.
12.1.14. Thermo Fisher Scientific Inc.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. ERYTHROPOIETIN STIMULATING AGENTS MARKET RESEARCH PROCESS
FIGURE 2. ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, 2023 VS 2030
FIGURE 3. ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ERYTHROPOIETIN STIMULATING AGENTS MARKET DYNAMICS
FIGURE 7. ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ERYTHROPOIETIN STIMULATING AGENTS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. ERYTHROPOIETIN STIMULATING AGENTS MARKET SHARE, BY KEY PLAYER, 2023

Companies Mentioned

  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Cipla Limited
  • Dr. Reddys Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Intas Pharmaceuticals Limited
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • LG Life Sciences Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information